Business Description
Cyclopharm Ltd
ISIN : AU000000CYC5
Total Employee Number:
109Compare
Compare
Traded in other countries / regions
CYC.Australia IPO Date
2007-01-18Description
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.86 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | -0.48 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.45 | |||||
Beneish M-Score | -1.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.5 | |||||
3-Year EBITDA Growth Rate | -38.5 | |||||
3-Year EPS without NRI Growth Rate | -20.8 | |||||
3-Year FCF Growth Rate | -25.5 | |||||
3-Year Book Growth Rate | -14.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 36.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.97 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 21.59 | |||||
9-Day RSI | 22.84 | |||||
14-Day RSI | 25.61 | |||||
3-1 Month Momentum % | -5.41 | |||||
6-1 Month Momentum % | -27.46 | |||||
12-1 Month Momentum % | -23.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.53 | |||||
Quick Ratio | 1.51 | |||||
Cash Ratio | 0.59 | |||||
Days Inventory | 326.71 | |||||
Days Sales Outstanding | 149.44 | |||||
Days Payable | 129.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.1 | |||||
Shareholder Yield % | -1.48 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 13.3 | |||||
Operating Margin % | -202.58 | |||||
Net Margin % | -103.16 | |||||
EBITDA Margin % | -96.08 | |||||
FCF Margin % | -116.44 | |||||
OCF Margin % | -103.82 | |||||
ROE % | -48.76 | |||||
ROA % | -31.47 | |||||
ROIC % | -95.73 | |||||
3-Year ROIIC % | -273.69 | |||||
ROC (Joel Greenblatt) % | -75.04 | |||||
ROCE % | -40.81 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1.97 | |||||
PS Ratio | 3.29 | |||||
PB Ratio | 2.05 | |||||
Price-to-Tangible-Book | 2.27 | |||||
EV-to-EBIT | -3.6 | |||||
EV-to-EBITDA | -4 | |||||
EV-to-Revenue | 3.84 | |||||
EV-to-Forward-Revenue | 6.66 | |||||
EV-to-FCF | -3.3 | |||||
Price-to-GF-Value | 0.6 | |||||
Price-to-Median-PS-Value | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 5.56 | |||||
Earnings Yield (Greenblatt) % | -27.78 | |||||
FCF Yield % | -30.83 |
Cyclopharm Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyclopharm Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.2:1 Stock Split | 2012-05-28 | 0.22 (+0.00%) | ||
| 1:1 Stock Split | 2008-10-21 | 0.46 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cyclopharm Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers